All news

Regeneron trades near 20 times earnings with

Alpha Vantage · The Motley Fool · · AI-summarised by FinFlash

Regeneron Pharmaceuticals has climbed over 40% in the past year, with 16 approved products and a robust pipeline. The company holds

Read original source

REGN company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.